CPET as a biomarker in FLD
Research type
Research Study
Full title
Exploring the potential of CardioPulmonary Exercise Testing as a biomarker in patients diagnosed with FIBrosing Lung Disease (the PETFIB study)
IRAS ID
220189
Contact name
Michael Gibbons
Contact email
Sponsor organisation
RD&E NHS FT
Duration of Study in the UK
1 years, 0 months, 0 days
Research summary
Patients with lung fibrosis (a progressive and ultimately fatal disease, which causes scarring to the lungs, shortness of breath, and limited capacity for physical exercise) have regular hospital check-ups where lung function tests are performed, to help determine whether the lung scarring is getting worse, or whether the patient is benefiting from any drug treatment they are receiving. However these tests are performed at rest, while seated, and do not indicate the impairment to physical mobility faced by patients in the real-world. Our pilot study aims to investigate whether a more accurate and relevant test, called cardiopulmonary exercise testing (CPET), will give a better indication of disease progression, quality of life and, crucially, whether a patient is responding (or likely to respond) to a particular drug treatment – either as part of their standard care, or during clinical trials for newer, better therapies. Further down the line, CPET will then be combined with a supervised exercise training programme to optimise the known benefits of physical exercise for the health of patients with chronic lung diseases such as lung fibrosis.
REC name
South West - Frenchay Research Ethics Committee
REC reference
17/SW/0059
Date of REC Opinion
25 May 2017
REC opinion
Further Information Favourable Opinion